| NAUT Stock | | | USD 2.40 0.02 0.84% |
Nautilus Biotechnology financial indicator trend analysis is infinitely more than just investigating Nautilus Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nautilus Biotechnology is a good investment. Please check the relationship between Nautilus Biotechnology Total Current Liabilities and its Non Currrent Assets Other accounts. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in employment.
For more information on how to buy Nautilus Stock please use our
How to Invest in Nautilus Biotechnology guide.
Total Current Liabilities vs Non Currrent Assets Other
Total Current Liabilities vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Nautilus Biotechnology Total Current Liabilities account and
Non Currrent Assets Other. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Nautilus Biotechnology's Total Current Liabilities and Non Currrent Assets Other is 0.92. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Nautilus Biotechnology, assuming nothing else is changed. The correlation between historical values of Nautilus Biotechnology's Total Current Liabilities and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Nautilus Biotechnology are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Total Current Liabilities i.e., Nautilus Biotechnology's Total Current Liabilities and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.92 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Total Current Liabilities
Total Current Liabilities is an item on Nautilus Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nautilus Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from Nautilus Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nautilus Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in employment.
For more information on how to buy Nautilus Stock please use our
How to Invest in Nautilus Biotechnology guide.
Selling General Administrative is likely to drop to about 25.5
M in 2024.
Enterprise Value Over EBITDA is likely to drop to -5.49 in 2024
Nautilus Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Nautilus Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nautilus Biotechnology fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to
measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to
predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.